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Summary
 
CD4
 
1
 
 T cells play a critical role in generating and maintaining immune responses against
pathogens and alloantigens, and evidence suggests an important role for them in antitumor im-
munity as well. Although major histocompatibility complex class II–restricted human CD4
 
1
 
 T
cells with specific antitumor reactivities have been described, no standard method exists for
cloning the recognized tumor-associated antigen (Ag). In this study, biochemical protein puri-
fication methods were used in conjunction with novel mass spectrometry sequencing tech-
niques and molecular cloning to isolate a unique melanoma Ag recognized by a CD4
 
1
 
 tumor-
 
infiltrating lymphocyte (TIL) line. The HLA-DR
 
b
 
1*0101–restricted Ag was determined to be
a mutated glycolytic enzyme, triosephosphate isomerase (TPI). A C to T mutation identified
by cDNA sequencing caused a Thr to Ile conversion in TPI, which could be detected in a
tryptic digest of tumor-derived TPI by mass spectrometry. The Thr to Ile conversion created a
neoepitope whose T cell stimulatory activity was enhanced at least 5 logs compared with the
wild-type peptide. Analysis of T cell recognition of serially truncated peptides suggested that
the mutated amino acid residue was a T cell receptor contact. Defining human tumor Ag rec-
ognized by T helper cells may provide important clues to designing more effective immuno-
therapies for cancer.
Key words: melanoma • antigen • CD4
 
1
 
 T cells • HLA-DR1 • triosephosphate isomerase
 
D
 
uring the past decade, the field of human tumor im-
munology has evolved from describing interactions
between lymphocytes and tumor cells on a cellular level, to
dissecting mechanisms of tumor-specific immune recogni-
tion on a molecular and biochemical level. Attention has
been focused predominantly on tumor-specific CD8
 
1
 
 T
cells, since they exert important antitumor effector func-
tions in many in vivo murine tumor models. Methods have
been developed to identify MHC class I–restricted tumor-
associated Ag recognized by human CD8
 
1
 
 T cells, through
molecular cloning in stable or transient expression systems
(1, 2), or through direct mass spectrometric sequencing of
peptides eluted from tumor-derived MHC–peptide com-
plexes (3). The availability of these technologies has facili-
tated a tremendous expansion of our knowledge of com-
monly expressed as well as mutated tumor-associated Ags
recognized by MHC class I–restricted CD8
 
1
 
 T cells de-
rived from cancer patients (for a review, see reference 4).
Such knowledge has in turn led to the development of
experimental Ag-specific immunotherapies, which have
yielded encouraging clinical results (5). However, the par-
tial and transient nature of many of the observed clinical re-
sponses indicates a need to develop approaches that recruit
additional immunologic effector components.
CD4
 
1
 
 T cells play a central role in generating and main-
 
taining immune responses, through interactions with CD8
 
1
 
T cells and B cells, and in their capacity as memory cells.
There is ample evidence from murine tumor models to
suggest an important role for Th cells in regulating CTL-,
macrophage-, eosinophil-, and antibody-dependent path-
ways of antitumor immunity (for a review, see reference 6).
In humans, tumor-specific CD4
 
1
 
 T cells have been dem-
onstrated in patients with many different types of cancers
(6, 7), and we are just beginning to explore the nature of
the specific Ags which are recognized. However, no stan-
dard method exists to facilitate this area of study. The mo-
lecular methods used successfully in class I systems are not
directly applicable, due to the complexity of the class II– 
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restricted Ag processing pathway with its specialized pep-
tide loading component and requirement for accessory
molecules. Likewise, the peptide elution strategy is also not
readily applied, owing to the necessity for massive quantities
of tumor tissue (
 
.
 
10
 
11
 
 cells) for study. We have previously
identified tyrosinase as an Ag recognized by melanoma-spe-
cific CD4
 
1
 
 T cells from one patient (8, 9); however, this was
done in the context of screening candidate Ags already
known to be recognized by melanoma-specific CD8
 
1
 
 T
cells. Thus, there is a critical need to develop new tech-
niques for isolating and characterizing MHC class II–
restricted tumor Ags. Here, we describe the identification of
an HLA-DR1–restricted mutated triosephosphate isomerase
(TPI)
 
1
 
 epitope recognized by melanoma-specific CD4
 
1
 
 T
cells, using a strategy that combines biochemical purifica-
tion with mass spectrometric sequencing and molecular
cloning. This approach uses the exogenous route of Ag
processing characteristic of class II systems, for pulsing
components of subcellular compartments as well as sequen-
tially purified tumor-derived protein fractions onto APCs
for T cell recognition (8, 10, 11).
 
Materials and Methods
 
Cell Cultures.
 
T cell, B cell, and melanoma cell lines were
initiated from specimens derived from patient 1558, a 48-yr-old
Caucasian male who had a primary cutaneous melanoma lesion
resected from the right shoulder 13 yr before the development of
metastatic disease in multiple organ systems. Tumor-infiltrating
lymphocytes (TIL) were cultured from a subcutaneous metastasis
resected from patient 1558 according to methods described (12),
and were maintained in RPMI 1640 with 10% human AB serum
and recombinant IL-2 (600 IU/ml; Chiron) for up to 120 d
without Ag restimulation. Under these conditions, CD4
 
1
 
 T cells
selectively proliferated, reaching 
 
.
 
97% after 4 wk of culture, and
manifested specific recognition of autologous tumor cells which
constitutively expressed MHC class II molecules. Melanoma cul-
tures and EBV-transformed B cell lines were established in our
laboratory and maintained in RPMI 1640 with 10% FCS (13).
To grow large quantities of tumor cells for protein purification,
the 1558-mel line, which was initiated from the same metastatic
lesion used to generate TIL 1558, was maintained in 10-chamber
cell factories (Nunc International). The monocytic leukemia cell
line THP-1 (American Type Culture Collection) was grown in
RPMI 1640 with 10% FCS; before use as APCs, these cells were
cultured in the presence of IFN-
 
g
 
 100 U/ml for 48–96 h to up-
regulate expression of MHC class II molecules (14).
 
HLA Typing.
 
HLA serotypes and DNA genotypes of fresh
PBLs and cell lines were determined by the National Institutes of
Health HLA Laboratory, as described (10). The class II genotype
of patient 1558 was found to be HLA-DR
 
b
 
1*0101, 1101;
DQ
 
b
 
1*0301, 0501; DR
 
b
 
3*0202.
 
Assessment of T Cell Responses to Tumor Cells, Tumor Lysates,
Protein Fractions, and Peptides.
 
To assess recognition of whole
melanoma cells, CD4
 
1
 
 TIL 1558 were cultured in flat-bottomed
 
microtiter plates at 2 
 
3 
 
10
 
5
 
 cells/well, in the presence of irradi-
ated tumor cells (12,000 rad) at 10
 
5
 
/well for 20–24 h (15). To as-
sess T cell recognition of tumor lysates or fractionated tumor-
derived proteins, EBV-B cells or IFN-
 
g
 
–treated THP-1 cells
were used as APCs. APCs cultured at 1.5 
 
3 
 
10
 
5
 
 cells/well were
pulsed for 16–24 h with freeze–thaw lysates of tumor cells (1–2 
 
3
 
10
 
5
 
 cell equivalents/well) or fractionated proteins derived from
tumor cells (2 
 
3 
 
10
 
5
 
 to 8 
 
3 
 
10
 
7
 
 cell equivalents/well), after
which T cells were added for 20 h (10). Peptide recognition was
tested by pulsing APCs with peptides for 16–24 h, after which T
cells were added to the assay for 20 h (9). Culture supernatants
were then harvested, and GM-CSF secretion by CD4
 
1
 
 T cells
was measured using a commercially available ELISA kit (R&D
Systems; detection limit 8 pg/ml). In some experiments, anti-
MHC mAbs were used to inhibit specific Ag recognition by T
cells (10). Antibodies included L243 (against HLA-DR; IgG2a),
IVA12 (HLA-DR, DP, ?DQ; IgG1), Genox 3.53 and G2b.2
(HLA-DQw1, which includes the DQ
 
b
 
1*0501 genotype; IgG1
and IgG2b, respectively), IVD12 (HLA-DQw3; IgG1), and W6/
32 (HLA-A, B, C; IgG2a) (all purified from American Type Cul-
ture Collection hybridoma supernatants).
 
Preparation of Cell-free Extracts.
 
A total of 1.2 
 
3 
 
10
 
9
 
 adherent
1558-mel cells were harvested from cell factories with trypsin/
EDTA, and cell pellets were washed twice in ice-cold PBS and
stored dry at 
 
2
 
70
 
8
 
C. Cell homogenization was achieved by sus-
pending the cells in ice-cold sucrose buffer (150 mM sucrose, 2.5
mM dithiothreitol, 4 mM 4-[2-aminoethyl]-benzenesulfonyl flu-
oride hydrochloride) at a concentration of 10
 
8
 
 cells/ml and dis-
rupting them in a Wheaton Potter-Elvehjem tissue grinder. All
successive purification steps were carried out on ice or at 4
 
8
 
C.
Whole nuclei were separated from cytoplasm and membranes by
centrifugation at 800 
 
g
 
 for 10 min. Salts and protease inhibitors
were subsequently added to minimize protein degradation in the
supernatant. The mixture was adjusted to contain 50 mM Tris-
HCl, 150 mM NaCl, 10% glycerol, 1 mM benzamidine, and 2.5
mM Na-EDTA, pH 7.5. Leupeptin, pepstatin, antipain, aproti-
nin, and chymostatin were added at 25 
 
m
 
g/ml homogenate. The
cytosolic fraction was recovered by a high-speed centrifugation
step (31,500 
 
g
 
 for 60 min). The pellets which were recovered
constituted the membrane fraction. The supernatant (cytosol) un-
derwent addition of polyethyleneimine (PEI) 0.08% and centrifu-
gation to precipitate nucleic acids, followed by a three-step frac-
tionated ammonium sulfate precipitation saturating to 28, 52, and
75% with (NH
 
4
 
)2SO
 
4
 
. These fractions were dissolved in buffer A
(25 mM Tris-HCl, pH 8.0, 25 mM NaCl, 2 mM dithiothreitol, 1
mM benzamidine, 1 mM Na-EDTA) and stored at 
 
2
 
70
 
8
 
C if not
used directly for further purification. A portion of each subcellu-
lar fraction was dialyzed against PBS for testing in bioassays.
 
Chromatographic Purifications.
 
The cytosolic fraction saturated
to 75% with (NH
 
4
 
)2SO
 
4
 
 was desalted on Sephadex G25 M col-
umns with buffer A (described above) and loaded onto an anion
exchange chromatography column (HiTrap Q, 5 ml). Protein
was eluted with an increasing NaCl gradient in buffer A (0.25
mM to 1 M NaCl). Portions of the eluted protein fractions were
concentrated, equilibrated in PBS on Microcon-30 membrane
units (Amicon, Inc.), and tested for T cell recognition. Bioactive
fractions were then pooled and concentrated on a Centriprep-30
membrane unit (Amicon, Inc.) to 
 
z
 
2 mg protein/ml, and loaded
onto a Superdex 75 HiLoad 16/60 gel filtration column. After
testing individual eluted fractions for bioactivity, active fractions
were pooled and concentrated to 
 
z
 
1 mg protein/ml. For hydro-
phobic interaction chromatography, the solution was adjusted to
1.5 M (NH
 
4
 
)2SO
 
4
 
 in buffer A by overnight dialysis at 4
 
8
 
C. A de-
 
1
 
Abbreviations used in this paper:
 
 ID, inner diameter; MART, melanoma
antigen recognized by T cells; 
 
m
 
ESI, microelectrospray ionization; MS,
mass spectrometry; OD, outer diameter; TIL, tumor-infiltrating lympho-
cyte(s); TPI, triosephosphate isomerase. 
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creasing 1.5–0 M (NH
 
4
 
)2SO
 
4
 
 gradient in buffer A was performed
on a Resource Phe hydrophobic interaction column to yield an
active protein fraction with sufficient purity for sequence analysis.
All chromatography columns were purchased from Amersham
Pharmacia Biotech and applied on the AKTAexplorer liquid
chromatography system (Amersham Pharmacia Biotech). Indi-
vidual eluate fractions were analyzed by SDS-PAGE on 4–20%
acrylamide Tris-glycine precast gels (Novex) stained with Coo-
massie blue (Novex) or silver stain (Bio-Rad Laboratories).
 
Nano-HPLC Microelectrospray Ionization Mass Spectrometry and
Database Searching.
 
A bioactive purified protein fraction eluted
from the hydrophobic interaction column was equilibrated in
50 mM ammonium carbonate, pH 7.8, using Microcon-30
membrane concentrators, for sequence analysis. 5 
 
m
 
g of protein
was digested with 0.5 
 
m
 
g of modified trypsin (Promega) in a
50-
 
m
 
l vol at room temperature for 19 h. The digest was frozen at
–35
 
8
 
C until analyzed. An aliquot containing 
 
z
 
25 ng of digested
protein was analyzed by nano-HPLC microelectrospray ioniza-
tion (
 
m
 
ESI) mass spectrometry (MS). All mass spectrometric anal-
yses were performed on an LCQ ion trap mass spectrometer
(Finnigan). The ESI head supplied with the instrument was
removed and replaced with a 
 
m
 
ESI source. The ESI voltage
(1.5–1.8 kV) was applied via a stainless steel union placed on the
HPLC pump side of the reversed phase column. The 
 
m
 
ESI tips
were made from 360-
 
m
 
m outer diameter (OD), 75-
 
m
 
m inner di-
ameter (ID) fused silica capillary (Polymicro Technologies) pulled
to 
 
z
 
20-
 
m
 
m OD, 5-
 
m
 
m ID using a P-2000 laser puller (Sutter
Co.). The 
 
m
 
ESI tips were connected directly to a nano-HPLC
column using 350-
 
m
 
m ID Teflon tubing (Zues). Nano-HPLC
columns were prepared by packing 
 
z
 
10 cm of 5-
 
m
 
m C18 mate-
rial (YMC Corp.) inside 360-
 
m
 
m OD, 75-
 
m
 
m ID fused silica
capillary. Solvents A and B for HPLC were 0.1 M acetic acid in
water and 0.1 M acetic acid in 70% acetonitrile. The HPLC gra-
dient increased from 1 to 35% acetonitrile in 11 min. Variable
flow chromatography (Settlage, R.E., R.E. Christian, J. Shaba-
nowitz, and D.F. Hunt, manuscript submitted for publication;
patent pending), technology in which the mass spectrometer data
system controls the rate of sample introduction, was used for the
analysis of the protein digest. Flow rate for mobile phase into the
mass spectrometer was set at 
 
z
 
200 nl/min at the beginning of
the gradient, switched to 
 
,
 
50 nl/min shortly before peptides be-
gan to elute, and returned to 200 nl/min once peptides were no
longer detected. LCQ software programs used in the above ex-
periment included those for data-dependent data acquisition, dy-
namic exclusion, and isotope exclusion. For data-dependent anal-
ysis, the instrument was programmed to continuously cycle
through six scan events. Scan event 1 was an MS scan from 300
to 2,000 m/z. Scan events 2–6 were MS/MS scans on the five
most abundant ions detected in scan event 1. The dynamic exclu-
sion settings were as follows: 6 amu 
 
5 
 
exclusion width; 2 min 
 
5
 
exclusion duration; 30 s 
 
5 
 
preexclusion duration. The isotope
exclusion window was set to 4 amu. MS/MS spectra were ana-
lyzed using the SEQUEST (16, 17) search program, a database
search algorithm capable of searching thousands of MS/MS spec-
tra consecutively and automatically. SEQUEST compares experi-
mental MS/MS spectra with theoretical MS/MS spectra of pep-
tides derived from proteins in protein databases. Peptides from
the protein databases are scored and ranked based on the similar-
ity between the experimental and theoretical spectra. SEQUEST
settings were as follows: parent ion mass tolerance 
 
5 
 
2.0 amu;
fragment ion mass tolerance 
 
5 
 
0.4 amu; enzyme 
 
5 
 
trypsin;
group scans 
 
5 
 
40 scans; group scan parent tolerance 
 
5 
 
0.5 amu;
and no amino acid modifications.
 
Expression Cloning of TPI.
 
Total RNA was prepared from
1558-mel and 1558-EBV B cells using the Trizol reagent
(GIBCO BRL), and mRNA was subsequently prepared from
1558-mel (PolyATract mRNA Isolation Systems; Promega).
First-strand cDNA was synthesized (Superscript Preamplification
System; GIBCO BRL) followed by PCR amplification of TPI
(sequence data available from EMBL/GenBank/DDBJ under ac-
cession no. M10036). The 5
 
9
 
 oligonucleotide primer, 5
 
9
 
-AAAGG-
ATCCTCGGCTCGGCC
 
ATG
 
GCGCCCTCCAGGAAGTT-3
 
9,
contained an engineered BamHI restriction site at the 59 end (ini-
tiation codon in bold type). The 39 primer, 59-AAAGGTAC-
CTTACTTGTCATCGTCATCCTTGTAGTCTTGTTTGG-
CATTGATGAT-39, contained an engineered KpnI site as well
as a sequence encoding the 8-mer FLAG epitope DYKDDDDK
allowing for mAb-mediated detection of TPI on Western blots
(anti-FLAG M2 mAb; Sigma) (FLAG nucleotide sequence un-
derlined, stop codon in bold type). Oligonucleotide primers were
synthesized using an ABI 392 DNA/RNA synthesizer (Applied
Biosystems). The resulting PCR fragment was ligated into the
expression vector pCR3.1 (Eukaryotic TA Cloning Kit; Invitro-
gen), and ligation products were used to transform DH5-a
Escherichia coli (GIBCO BRL). Bacterial colonies harboring re-
combinant plasmids with correct sequence orientation were de-
tected by PCR. Plasmids were purified from bacterial clones us-
ing the QIAprep Spin Miniprep Kit (QIAGEN, Inc.). DNA
sequencing of TPI inserts was performed with T7 forward and
pCR3.1 reverse primers, or with the TPI sequence-specific
primers described above, using the Big Dye Terminator Cycle
Sequencing Kit (Perkin-Elmer/ABI). Sequences were deter-
mined with an ABI Prism 310 Genetic Analyzer (Perkin-Elmer).
To test CD41 T cell recognition of TPI, plasmids were trans-
fected transiently into COS-7 cells (gift of Warren Leonard, Na-
tional Institutes of Health) for 72 h with Lipofectamine Plus
(GIBCO BRL), after which cell lysates were prepared with re-
peated freeze–thaw cycles for pulsing onto APCs.
Peptide Synthesis. Peptides were synthesized and analyzed for
sequence and purity as described (9).
Results
HLA-DR1–restricted CD41 T Cell Recognition of a Unique
Autologous Tumor Ag. Most melanoma TIL cultures prop-
agated in IL-2 under standard culture conditions will be-
come predominantly CD81 after 3–4 wk (18); however,
TIL 1558 were .97% CD41 by 26 d. When stimulated
with MHC class II1 whole autologous tumor cells, either
fresh or cultured, these TIL specifically secreted GM-CSF,
IFN-g, and TNF-a, but not IL-2 or IL-4. As shown in
Fig. 1, TIL recognition of cultured 1558-mel, as measured
by GM-CSF secretion, was inhibited by mAb directed
against HLA-DR but not HLA-DQ or MHC class I mole-
cules. TIL 1558 also recognized autologous EBV-B cells
pulsed with lysates of 1558-mel, and mAb blocking experi-
ments similar to that shown in Fig. 1 confirmed HLA-DR
restriction. By using allogeneic B cell lines with known
HLA types to process and present tumor lysate, it was
determined that the operational restriction element was
HLA-DRb1*0101 (data not shown). The monocytic leu-
kemia cell line THP-1, which expresses the DRb1*0101
molecule, proved to have enhanced processing capabilities
for the 1558-mel Ag relative to EBV-B cell lines, and so760 MHC Class II–restricted Mutated Melanoma Antigen
was used as the APCs for tumor lysates and protein frac-
tions in all subsequent experiments.
Although CD41 TIL 1558 recognized autologous tumor
cells, they failed to react against autologous normal cells,
including cultured fibroblasts, EBV-B cells, and fresh PBLs.
To assess whether the melanoma Ag recognized by TIL
1558 was commonly expressed among other human tu-
mors, lysates were prepared from 45 different tumors for
processing by THP-1 cells and presentation to TIL. CD41
TIL 1558 were not stimulated by any lysates other than
those derived from fresh or cultured autologous melanoma
cells, including 19 allogeneic cultured melanomas, 7 fresh
melanomas, 5 colon carcinomas, 2 breast carcinomas, 3
prostate carcinomas, 1 pancreatic carcinoma, 4 sarcomas,
and 4 EBV-B cell lines (data not shown). These findings
suggested that the Ag recognized by TIL 1558 was in fact a
neoantigen resulting from a genetic mutation unique to the
autologous melanoma.
Identification of the Specific Tumor Ag Recognized by CD41
TIL 1558. The ability of TIL 1558 to recognize the
1558-mel Ag when processed by APCs through the exoge-
nous MHC class II pathway afforded an opportunity to
apply a protein purification strategy for Ag identification.
Through this approach, melanoma cells could be reduced
to subcellular compartments and then to sequentially puri-
fied protein fractions, which could be assayed for bioactiv-
ity by feeding them to APCs for T cell recognition. Impor-
tantly, since the recognized protein Ag would be processed
into smaller peptide fragments by APCs, it would not be
necessary to preserve tertiary protein structure during the
purification procedure.
Melanoma cells disrupted by douncing in the presence of
protease inhibitors were separated into nuclear, membrane,
and cytosolic fractions by differential centrifugation. The
cytosol was further fractionated by a stepwise (NH4)2SO4
precipitation, and each fraction was pulsed onto APCs for
T cell recognition. As shown in Fig. 2, the cytosol pro-
vided a much stronger stimulus for melanoma-specific T
cells than the membrane or nuclear fractions, and most of
the cytosolic activity precipitated at 75% (NH4)2SO4 satu-
ration. This finding was reproduced in two similar experi-
ments. Titration experiments demonstrated that the 75%
(NH4)2SO4 precipitate recovered from the cytosol was
5–25 times more stimulatory than the other fractions
tested, although the protein content of the various fractions
differed only by up to twofold (not shown). None of the
1558-mel fractions were capable of stimulating CD41 TIL
from another patient, and a cytosolic fraction prepared in a
similar manner from a renal cell carcinoma line failed to
stimulate TIL 1558. Thus, TIL 1558 seemed to recognize a
cytosolic (soluble) protein unique to 1558-mel.
To isolate the 1558-mel Ag, the active cytosolic fraction
was purified through a series of chromatographic separa-
tions. First, proteins that precipitated at 75% (NH4)2SO4
saturation were dissolved in buffer and applied to an anion
exchange column. When individual fractions eluted from
the column were pulsed onto APCs for T cell recognition,
it was found that the bioactivity remained in the column
run-through, and therefore the protein of interest had
failed to bind to the column. However, SDS-PAGE analy-
sis of all of the eluate fractions indicated that, although the
bioactive run-through contained a complex mixture of
proteins, many other proteins which lacked bioactivity
had bound and separated adequately on the column (not
shown); thus, a significant purification of the specific tumor
Figure 1. Melanoma-specific CD41 TIL 1558 are HLA-DR restricted.
TIL 1558 were coincubated with whole autologous 1558-mel cells for
20 h, in the absence or presence of anti-MHC mAb, and specific Ag rec-
ognition was measured by GM-CSF secretion. As a control for mAb
blocking, the MART-1–specific, HLA-A2–restricted CD81 TIL 1088
line was cocultured with its autologous 1088-mel. CD41 TIL 1558 were
inhibited by mAbs directed against HLA-DR (L243) and a monomorphic
class II determinant (IVA12), whereas the CD81 TIL were inhibited only
by an anti–class I mAb (W6/32).
Figure 2. CD41 TIL 1558 recognize a cytosolic Ag. THP-1 cells (1.5 3
105 cells/well) were used as APCs for an unfractionated freeze–thaw ly-
sate of 1558-mel, or for various subcellular fractions (2 3 105 cells equiv-
alents/well) in a microtiter assay. CY1, unfractionated cytosol; CY2, cy-
tosol precipitated at 50% (NH4)2SO4 saturation; CY3, cytosol
precipitated at 75% (NH4)2SO4; CY4, proteins solubilized in 0.5 M KCl
from a polyethyleneimine (PEI) precipitate of CY1; M1, membrane-
bound proteins solubilized in 0.5 M KCl; M2, membrane proteins solubi-
lized in 2% CHAPS detergent; N, nuclear fraction. T cell reactivity
against protein-pulsed APCs was measured by GM-CSF secretion.761 Pieper et al.
Ag had been achieved. Next, the bioactive material recov-
ered after anion exchange chromatography was separated
according to molecular size on a gel filtration column. The
results of testing individual fractions for T cell recognition
are shown in Fig. 3, demonstrating a peak of bioactivity in
eluate fractions 20–23, with GM-CSF secretion by TIL in
response to fraction 21 reaching 371-fold above back-
ground secretion (29,300 compared with 79 pg/ml). Al-
though a significant purification was achieved at this step,
SDS-PAGE indicated that the bioactive fractions still con-
tained a complex mixture of proteins. The final chromato-
graphic purification was performed by combining the bio-
active gel filtration fractions and applying them to a
hydrophobic interaction column. Fig. 4 shows that this
procedure yielded two highly bioactive fractions, numbers 4
and 6. Each appeared to contain a single protein band of
z30 kD on SDS-PAGE.
Fraction 6, which was eluted from the hydrophobic
interaction column, was subjected to tryptic cleavage fol-
lowed by nano-HPLC mESI ion trap MS. Using data-
dependent data acquisition, dynamic exclusion, isotope
exclusion, and SEQUEST database searching, 19 peptide
sequences were obtained, representing a total of 187 amino
acids, and all were identified as nonmutated human TPI. In
addition, eluate fraction 4 was subjected to NH2-terminal
sequencing with Edman degradation, yielding an 11–amino
acid sequence corresponding to residues 2–12 of TPI. No
other proteins were identified in these fractions. The com-
plete TPI sequence (GenBank accession no. M10036) con-
tains 249 amino acids with a calculated molecular mass of
26,700 daltons, corresponding to the observed mass of the
1558-mel Ag on SDS-PAGE.
Characterization of the Mutated TPI Epitope Recognized by
CD41 TIL 1558. To confirm that TPI was indeed the
tumor-specific Ag recognized by TIL 1558, cDNA encod-
ing TPI was amplified from mRNA derived from 1558-
mel, the cell line which stimulated CD41 TIL, as well as
from the autologous B cell line 1558-EBV, which did not
stimulate TIL. TPI was cloned into a eukaryotic expression
vector, and recombinant plasmids derived from individual
bacterial colonies were transiently transfected into COS-7
cells. COS transfectants expressing TPI protein were then
pulsed onto APCs as freeze–thaw lysates, for T cell recog-
nition.
Table I shows the results of testing individual TPI clones
derived from 1558-mel for T cell recognition. TPI en-
Figure 3. Purification of the 1558-mel Ag by size exclusion chroma-
tography. Gel filtration chromatography was used, after anion exchange
chromatography, to separate proteins derived from the 1558-mel cytosol
according to size. SDS-PAGE of the eluted protein fractions is shown (gel
stained with Coomassie blue), as well as the results of the corresponding
bioassay. T cell recognition of APCs pulsed with individual protein frac-
tions (4 3 107 cell equivalents/well) is shown as stimulation index, the
fold specific secretion of GM-CSF above background secretion (T cells
plus unpulsed APCs).
Figure 4. Purification of the 1558-mel Ag by hydrophobic interaction
chromatography. Individual eluate fractions (5 3 107 cell equivalents/
well) were pulsed onto APCs for T cell recognition. SDS-PAGE (silver
stain) shows that bioactive fractions 4 and 6 appear to contain a single
protein band of z30 kD. The protein in fraction 6 was sequenced via
mass spectrometric analysis, identifying it as TPI. This was confirmed by
NH2-terminal Edman degradation sequencing of fraction 4.762 MHC Class II–restricted Mutated Melanoma Antigen
coded by three clones (designated 1B, 5B, and 11G) stimu-
lated T cells, as manifested by GM-CSF secretion, while
three other TPI clones were not stimulatory, nor was a
b-actin clone used as a negative control. Western blotting
with the anti-FLAG mAb, directed against a specific 8-mer
sequence fused to the COOH terminus of each of these
proteins, confirmed that all recombinant proteins were ex-
pressed in COS-7 cells at comparable levels (not shown).
DNA sequencing demonstrated that the three TPI clones
encoding a product recognized by T cells shared a missense
mutation at nucleotide position 450, consisting of a C to T
substitution. The effect of this mutation was to convert the
wild-type threonine (ACT) at amino acid position 28 to an
isoleucine (ATT). TPI clones 4B, 12A, and 12F, also de-
rived from 1558-mel, did not contain this mutation and
were not recognized by T cells. As an incidental finding, all
six TPI clones derived from 1558-mel shared two silent
nucleotide substitutions, at positions 652 (A to G) and 856
(C to G), presumed to represent DNA polymorphisms.
Thus, the six TPI clones obtained from 1558-mel repre-
sented two alleles, one wild-type, the other containing a
unique mutation. The nucleotide substitution at position
450 was not identified in six clones derived from 1558-
EBV, suggesting that this was indeed a somatic mutation
which had occurred in the tumor, and not an allelic poly-
morph.
To confirm that the mutated TPI protein predicted by
DNA sequencing was in fact present in 1558-mel cells, a
novel mass spectrometric sequence analysis computer pro-
gram was applied, which generated z5,000 mutant TPI se-
quences that differed from the wild-type sequence by a sin-
gle amino acid. The MS/MS data from the TPI digest was
then searched against the 5,000 mutant TPI sequences us-
ing SEQUEST programmed with the same settings as de-
scribed in Materials and Methods. This experiment de-
tected a new tryptic peptide corresponding to TPI residues
20–33, in which Thr at position 28 was substituted with ei-
ther Ile or Leu. No other mutant peptides were detected in
this analysis.
To further investigate the effect of the TPI mutation on
T cell reactivity, peptides encompassing the site of muta-
tion were synthesized and assessed for recognition by TIL
1558. A wild-type 15-mer peptide, TPI 23–37, was syn-
thesized with the sequence GELIGTLNAAKVPAD, as
well as a mutant peptide containing Ile instead of Thr at
position 28 (TPImut). As shown in Fig. 5, T cell recognition
of the mutated peptide was enhanced at least 5 logs com-
pared with the wild-type. Also of note, subnanomolar con-
centrations of the mutant peptide were recognized consis-
tently, reminiscent of the extremely sensitive CD41 T cell
responses typically observed against foreign microbial epi-
topes. This is in contrast to the CD41 T cell recognition of
nonmutated melanoma-associated tyrosinase epitopes de-
scribed previously (9), which required peptide concentra-
tions of 10 mM or more for half-maximal stimulation.
Finally, we wished to determine the immunologic func-
tion of the TPI mutation; that is, whether the mutated
amino acid constituted an MHC-binding residue or a TCR
contact. A substantial amount of information is available
concerning the binding motif of peptides complexed to
HLA-DRb1*0101, which is the restriction element for
TPImut 23–37 as demonstrated by mAb blocking studies and
peptide presentation by allogeneic HLA-compatible APCs
(not shown). The crystal structure of this HLA molecule
complexed to a high-affinity peptide, influenza HA 306–
318, reveals that the peptide binding site has one large hy-
drophobic pocket accommodating the P1 peptide anchor
residue, which is the major determinant of peptide binding
(19). The crystal structure of HLA-DRb1*0101 also dem-
onstrates shallower, less hydrophobic pockets accommodat-
ing the P4, P6, P7, and P9 peptide anchor residues. Inspec-
tion of the sequences of peptides naturally binding to this
Table I. Recognition of Mutated TPI by CD41 TIL 1558
Stimulator
cell lysate
Transfected 
gene
cDNA sequence,
nucleotide 450 GM-CSF 
pg/ml
1558-mel None T, C 6,315
1558-EBV None C ,8
COS-7 TPI-1B T 3,485
COS-7 TPI-5B T 8,310
COS-7 TPI-11G T 6,340
COS-7 TPI-4B C 8
COS-7 TPI-12A C 11
COS-7 TPI-12F C 11
COS-7 b-actin n.a. ,8
COS-7 cells were transfected for 4 d with the indicated genes. Cell ly-
sates were then incubated with THP-1 monocytic leukemia cells for
20 h, after which TIL were added for 20 h. GM-CSF secretion by TIL
was measured by ELISA. n.a., not applicable.
Figure 5. Enhanced recognition of a mutated TPI peptide by CD41
TIL 1558. 15-mer peptides containing a wild-type (open circles) or mu-
tated (filled circles) sequence were pulsed onto THP-1 cells for recogni-
tion by T cells. T cell secretion of GM-CSF in response to peptide stimu-
lation was measured by ELISA. Background secretion of GM-CSF by
TIL cultured with THP-1 cells in the absence of peptide was undetect-
able (,8 pg/ml).763 Pieper et al.
MHC allele (20), as well as monitoring the effects of substi-
tuted analogues and truncated peptides on MHC binding
(21), have confirmed the overriding importance of the hy-
drophobic P1 anchor and lesser roles for the other four an-
chor residues. In the case of the TPImut 23–37 peptide, po-
tential P1 anchors include the hydrophobic residues Leu 25
and Ile 26, and the mutation itself, Ile 28. A series of trun-
cated peptides were tested for T cell recognition, and as
shown in Table II, Leu 25 was unimportant whereas Ile 26
was required for stimulating CD41 TIL 1558. If Ile 26
were indeed the P1 anchor, then Val 34 would be the P9
anchor, and serial truncations at the COOH terminus of
TPImut 23–37 confirmed that peptides lacking the Val 34 res-
idue were not recognized. These data identify the 9–amino
acid MHC binding core of the mutated TPI epitope as ex-
tending from Ile 26 to Val 34, and suggest that the site of
mutation, Ile 28, is a TCR contact, as it resides in the P3
position. For peptides binding to HLA-DRb1*0101, the
role of the P3 residue as a TCR contact has been shown by
crystal structure as well as by studies of substituted synthetic
analogues which competitively inhibit TCR engagement
(22, 23).
Discussion
This study describes the isolation and characterization
of a mutated MHC class II–restricted human tumor Ag
through a multimodality approach that combines biochem-
ical fractionation, mass spectrometric sequencing, and mo-
lecular cloning. Monach et al. have used a similar strategy
to identify a class II–restricted murine tumor Ag (11); to
our knowledge, this report is the first successful human ap-
plication. This approach to Ag identification is uniquely
suited to class II systems, in which Ag pulsed exogenously
onto APCs can access the endosomal processing compart-
ment (24). Since the end-point bioassay measures the pres-
ence of a processed peptide rather than an intact protein,
the biochemical purification procedures need not preserve
native tertiary structure. This represents a convenient ad-
vantage relative to traditional applications of similar protein
purification schemes, such as those used in enzymology.
Another innovation is the use of MS to sequence the puri-
fied protein. The combination of HPLC and ion trap MS
has made it possible to sequence peptides at the 20–50 amol
level. This technique is particularly well suited for sequenc-
ing proteins in complex mixtures and for characterizing
posttranslational modifications. These features render mass
spectrometric sequencing eminently suited for situations in
which limited quantities of material are available, and for
subtractive approaches comparing the constituents of two
or more partially purified protein fractions with known
bioactivities.
The protein containing the mutation recognized by
CD41 TIL 1558, TPI (EC 5.3.1.1), is an enzyme that cata-
lyzes the interconversion of dihydroxyacetone phosphate
and glyceraldehyde 3-phosphate, a critical step for generat-
ing energy in the glycolytic pathway. Its sequence is highly
conserved among species, with z50% amino acid homol-
ogy between E. coli and humans, and human TPI is consid-
ered to have evolved into a “perfect enzyme,” with one of
the highest catalytic rates known (25). TPI is found among
the dozen or so predominant proteins in two-dimensional
gel databases generated from human tumors (26–28), which
is not surprising in view of its energy-generating function
as well as its link to nucleotide synthesis via the pentose
phosphate shunt. Studies of thousands of individuals have
failed to detect allelic variants of TPI (29). The several de-
scribed mutant forms of the enzyme are all linked to hu-
man deficiency diseases; mutations at nucleotide position
450, associated with 1558-mel, have not been reported.
However, there is evidence for a causal relationship be-
tween UV irradiation, an agent implicated in generating
Table II. Determining the PI Anchor Residue for TPImut 23–37
TPImut residues Sequence GM-CSF 
pg/ml
23–37 G E L I G I L N A A K V P A D 25,390
24–37 E L I G I L N A A K V P A D 28,460
25–37 L I G I L N A A K V P A D 11,750
26–38 I G I L N A A K V P A D T  7,210
27–39 G I L N A A K V P A D T E 38
28–40 I L N A A K V P A D T E V  22
29–41 L N A A K V P A D T E V V 34
20–34 Q S L G E L I G I L N A A K V 5,960
20–33 Q S L G E L I G I L N A A K 35
20–32 Q S L G E L I G I L N A A 25
20–31 Q S L G E L I G I L N A 24
THP-1 cells pretreated with IFN-g were pulsed overnight with the indicated peptides at 100 nM, then T cells were added for 20 h. GM-CSF se-
cretion by T cells was measured by ELISA. Background secretion of T cells plus THP-1 without peptide 5 28 pg/ml.764 MHC Class II–restricted Mutated Melanoma Antigen
melanomas in vivo, and C to T nucleotide substitutions
such as occurred in 1558-mel (30). Indeed, C to T muta-
tions have been shown to generate MHC class I–restricted
neoantigens recognized by CD81 T cells from two mela-
noma patients. In those two instances, functional mutations
in cyclin-dependent kinase 4 (31) and b-catenin (32) may
have conferred an oncogenic advantage on the tumor cells,
which could have counterbalanced or outweighed the neg-
ative effect of disclosing the tumor to immune recognition.
The crystal structure of TPI indicates that Thr 28, the site
of the 1558-mel mutation, is not located at an active cata-
lytic site (33); in fact, deliberate attempts to enhance the
function of TPI through site-directed mutagenesis of cata-
lytic site residues have not been successful (34). However,
one might speculate that the nonconservative Thr28Ile
mutation could impact on the tertiary structure of the en-
zyme and hence its catalytic function, and the potential role
of this mutation in enhancing TPI function will be ex-
plored in future studies.
By immunohistochemical analysis, the subcutaneous mel-
anoma metastasis from which TIL 1558 were derived ex-
pressed the shared immunogenic melanoma-associated pro-
teins tyrosinase, gp100, and melanoma antigen recognized
by T cells (MART)-1 (35). Nevertheless, CD41 TIL 1558
failed to react against these commonly expressed, nonmu-
tated Ags, instead responding to a unique neoantigen.
These TIL are representative of the majority of MHC class
II–restricted melanoma-specific CD41 T cells analyzed
from nine patients, among which two recognized the com-
monly expressed nonmutated tyrosinase Ag, while the rest
reacted against unique tumor-specific Ag (8, 10, 36, and
our unpublished data). The apparent dichotomy between
melanoma Ag recognized by CD41 versus CD81 T cells
(unique versus shared Ag) may reflect events occurring
during T cell development, with selective deletion of CD41
but not CD81 T cells reactive with lineage-specific “self”
Ag expressed in melanomas. Since melanocytes do not nor-
mally reside in the thymus during development, their Ags
would be represented there by migrating APCs which had
ingested and processed these Ags, preferentially leading to
presentation on MHC class II molecules and deletion of class
II–restricted Th cells. Thus, while it is important to iden-
tify shared tumor-associated Ags recognized by both CD41
and CD81 T cells for devising more effective immunother-
apies, it is also necessary to define optimally potent Ags
which can mediate tumor rejection. These may not be one
and the same, and immunotherapies incorporating unique
neoantigens may be required to realize the full potential of
this treatment modality.
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